Leonid S. Metelitsa

Houston Methodist — United States

Medicine · Health Sciences

4h-index186citations88works59.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(51), CAR-T cell therapy research(28), Cancer, Hypoxia, and Metabolism(18), Immune Cell Function and Interaction(13), Cancer Immunotherapy and Biomarkers(11)

Publications88 total

Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2024· 6 citedOpen Access
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Nature·2024· 155 citedOpen Access
Off-the-Shelf CD19-Specific CAR-NKT Cells in Patients with Relapsed or Refractory B-Cell Malignancies
Transplantation and Cellular Therapy·2024· 18 cited
Data from NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
2023Open Access
Data from NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
2023Open Access
Supplementary Data from NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
2023Open Access
Supplementary Data from NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
2023Open Access
Supplemental Figure 4 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Figure Legends from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Data from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Figure 2 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Data from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Figure 5 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Figure Legends from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Figure 1 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Figure 5 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Figure 6 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Figure 3 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Figure 4 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
Supplemental Table 1 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Anna Lakoma(21), Zaowen Chen(21), Eugene S. Kim(21), Jason M. Shohet(21), Amy N. Courtney(19), Malcolm K. Brenner(14), Stephen Gottschalk(13), Bilal Omer(13), Cliona M. Rooney(13), Daofeng Liu(12), John Hicks(12), Robin Parihar(12), Thomas Shum(10), Haruko Tashiro(10), Robert L. Kruse(10), Dimitrios L. Wagner(10), Kathan Parikh(10), Zhongzhen Yi(10), Tim Sauer(10), Paul Castillo(10)